These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 37574431)

  • 41. Clinical Outcomes of Golimumab as First, Second or Third Anti-TNF Agent in Patients with Moderate-to-Severe Ulcerative Colitis.
    Taxonera C; Rodríguez C; Bertoletti F; Menchén L; Arribas J; Sierra M; Arias L; Martínez-Montiel P; Juan A; Iglesias E; Algaba A; Manceñido N; Rivero M; Barreiro-de Acosta M; López-Serrano P; Argüelles-Arias F; Gutierrez A; Busquets D; Gisbert JP; Olivares D; Calvo M; Alba C;
    Inflamm Bowel Dis; 2017 Aug; 23(8):1394-1402. PubMed ID: 28671873
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Systematic review with network meta-analysis: the impact of medical interventions for moderate-to-severe ulcerative colitis on health-related quality of life.
    Paschos P; Katsoula A; Salanti G; Giouleme O; Athanasiadou E; Tsapas A
    Aliment Pharmacol Ther; 2018 Dec; 48(11-12):1174-1185. PubMed ID: 30378141
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A real life comparison of the effectiveness of adalimumab and golimumab in moderate-to-severe ulcerative colitis, supported by propensity score analysis.
    Renna S; Mocciaro F; Ventimiglia M; Orlando R; Macaluso FS; Cappello M; Fries W; Mendolaro M; Privitera AC; Ferracane C; Pisana V; Magnano A; Pluchino D; Inserra G; Scarpulla G; Garufi S; Carroccio A; Siringo S; Di Mitri R; Cottone M; Orlando A
    Dig Liver Dis; 2018 Dec; 50(12):1292-1298. PubMed ID: 30007516
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Real-world treatment patterns and disease control over one year in patients with inflammatory bowel disease in Brazil.
    Sassaki LY; Miszputen SJ; Kaiser Junior RL; Catapani WR; Bafutto M; Scotton AS; Zaltman C; Baima JP; Ramos HS; Faria MAG; Gonçalves CD; Guimaraes IM; Flores C; Amarante HMBS; Nones RB; Parente JML; Lima MM; Chebli JM; Ferrari MLA; Campos JF; Sanna MGP; Ramos O; Parra RS; da Rocha JJR; Feres O; Feitosa MR; Caratin RF; Senra JT; Santana GO
    World J Gastroenterol; 2021 Jun; 27(23):3396-3412. PubMed ID: 34163120
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Tofacitinib in Patients with Ulcerative Colitis: Inflammatory Bowel Disease Questionnaire Items in Phase 3 Randomized Controlled Induction Studies.
    Dubinsky MC; DiBonaventura M; Fan H; Bushmakin AG; Cappelleri JC; Maller E; Thorpe AJ; Salese L; Panés J
    Inflamm Bowel Dis; 2021 Jun; 27(7):983-993. PubMed ID: 32794567
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Randomized trial of tofacitinib in active ulcerative colitis: analysis of efficacy based on patient-reported outcomes.
    Panés J; Su C; Bushmakin AG; Cappelleri JC; Mamolo C; Healey P
    BMC Gastroenterol; 2015 Feb; 15():14. PubMed ID: 25651782
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Changes in health-related quality of life and work-related outcomes for patients with mild-to-moderate ulcerative colitis receiving short-term and long-term treatment with multimatrix mesalamine: a prospective, open-label study.
    Willian MK; D'Haens G; Yarlas A; Joshi AV
    J Patient Rep Outcomes; 2018 Dec; 2():22. PubMed ID: 30294708
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The effects of infliximab therapy on health-related quality of life in ulcerative colitis patients.
    Feagan BG; Reinisch W; Rutgeerts P; Sandborn WJ; Yan S; Eisenberg D; Bala M; Johanns J; Olson A; Hanauer SB
    Am J Gastroenterol; 2007 Apr; 102(4):794-802. PubMed ID: 17324131
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Prospective cohort study of appendicectomy for treatment of therapy-refractory ulcerative colitis.
    Stellingwerf ME; Sahami S; Winter DC; Martin ST; D'Haens GR; Cullen G; Doherty GA; Mulcahy H; Bemelman WA; Buskens CJ
    Br J Surg; 2019 Nov; 106(12):1697-1704. PubMed ID: 31393608
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Comparative Efficacy and Speed of Onset of Action of Infliximab vs Golimumab in Ulcerative Colitis.
    Singh S; Proudfoot JA; Dulai PS; Xu R; Feagan BG; Sandborn WJ; Jairath V
    Clin Gastroenterol Hepatol; 2020 Feb; 18(2):424-431.e7. PubMed ID: 31108227
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Effectiveness and Safety of Golimumab in Treating Outpatient Ulcerative Colitis: A Real-Life Prospective, Multicentre, Observational Study in Primary Inflammatory Bowel Diseases Centers.
    Tursi A; Allegretta L; Buccianti N; Della Valle N; Elisei W; Forti G; Faggiani R; Gallina S; Hadad Y; Larussa T; Lauria A; Luzza F; Lorenzetti R; Mocci G; Penna A; Polimeni N; Pranzo G; Ricciardelli C; Zampaletta C; Picchio M
    J Gastrointestin Liver Dis; 2017 Sep; 26(3):239-244. PubMed ID: 28922435
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The effect of intravenous golimumab on health-related quality of life in rheumatoid arthritis: 24-week results of the phase III GO-FURTHER trial.
    Bingham CO; Weinblatt M; Han C; Gathany TA; Kim L; Lo KH; Baker D; Mendelsohn A; Westhovens R
    J Rheumatol; 2014 Jun; 41(6):1067-76. PubMed ID: 24786931
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Peficitinib, an Oral Janus Kinase Inhibitor, in Moderate-to-severe Ulcerative Colitis: Results From a Randomised, Phase 2 Study.
    Sands BE; Sandborn WJ; Feagan BG; Lichtenstein GR; Zhang H; Strauss R; Szapary P; Johanns J; Panes J; Vermeire S; O'Brien CD; Yang Z; Bertelsen K; Marano C;
    J Crohns Colitis; 2018 Nov; 12(10):1158-1169. PubMed ID: 29917064
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trial.
    Peyrin-Biroulet L; Hart A; Bossuyt P; Long M; Allez M; Juillerat P; Armuzzi A; Loftus EV; Ostad-Saffari E; Scalori A; Oh YS; Tole S; Chai A; Pulley J; Lacey S; Sandborn WJ;
    Lancet Gastroenterol Hepatol; 2022 Feb; 7(2):128-140. PubMed ID: 34798039
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The association between disease activity and patient-reported outcomes in patients with moderate-to-severe ulcerative colitis in the United States and Europe.
    Armuzzi A; Tarallo M; Lucas J; Bluff D; Hoskin B; Bargo D; Cappelleri JC; Salese L; daCosta DiBonaventura M
    BMC Gastroenterol; 2020 Jan; 20(1):18. PubMed ID: 31964359
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Impact of adalimumab on disease burden in moderate-to-severe ulcerative colitis patients: The one-year, real-world UCanADA study.
    Bessissow T; Nguyen GC; Tarabain O; Peyrin-Biroulet L; Foucault N; McHugh K; Ruel J
    World J Gastroenterol; 2022 Sep; 28(34):5058-5075. PubMed ID: 36160646
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Therapeutic thresholds for golimumab serum concentrations during induction and maintenance therapy in ulcerative colitis: results from the GO-LEVEL study.
    Samaan MA; Cunningham G; Tamilarasan AG; Beltran L; Pavlidis P; Ray S; Mawdsley J; Anderson SH; Sanderson JD; Arkir Z; Irving PM
    Aliment Pharmacol Ther; 2020 Jul; 52(2):292-302. PubMed ID: 32506695
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The effect of golimumab therapy on disease activity and health-related quality of life in patients with ankylosing spondylitis: 2-year results of the GO-RAISE trial.
    van der Heijde D; Deodhar A; Braun J; Mack M; Hsu B; Gathany TA; Inman RD; Han C;
    J Rheumatol; 2014 Jun; 41(6):1095-103. PubMed ID: 24737912
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Tofacitinib in Patients with Ulcerative Colitis: Health-Related Quality of Life in Phase 3 Randomised Controlled Induction and Maintenance Studies.
    Panés J; Vermeire S; Lindsay JO; Sands BE; Su C; Friedman G; Zhang H; Yarlas A; Bayliss M; Maher S; Cappelleri JC; Bushmakin AG; Rubin DT
    J Crohns Colitis; 2018 Jan; 12(2):145-156. PubMed ID: 29028981
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Impairment of health-related quality of life in patients with inflammatory bowel disease: a Spanish multicenter study.
    Casellas F; Arenas JI; Baudet JS; Fábregas S; García N; Gelabert J; Medina C; Ochotorena I; Papo M; Rodrigo L; Malagelada JR
    Inflamm Bowel Dis; 2005 May; 11(5):488-96. PubMed ID: 15867589
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.